Microdosing GLP-1 Trends for Hashimoto’s Patients: Risks, Myths & Red Flags

Microdosing GLP-1 Trends for Hashimoto’s Patients: Risks, Myths & Red Flags Welcome to CFP Weight Loss. I'm Russell Clark, Nurse Practitioner. Today, we're exploring Microdosing GLP-1 Trends for Hashimoto’s Patients: Risks, Myths & Red Flags. ... Let's slow down for a moment and ground this in solid research — not hype, not trends, just what the science supports. ... We'll touch on Microdosing GLP-1, Hashimoto's Thyroiditis, Tirzepatide Risks — especially as they apply to real people over forty. ... Microdosing GLP-1 agonists like tirzepatide and semaglutide has surged in popularity among people managing autoimmune thyroid conditions. Hashimoto’s patients, often battling stubborn weight gain, fatigue, and metabolic slowdown, are exploring lower “micro” doses hoping for benefits with fewer side effects. While some report improved energy and modest fat loss, the trend carries important caveats. Understanding the interplay between GLP-1 modulation, thyroid autoimmunity, and metabolic markers is essential before experimenting. ... First — the appeal of microdosing in hashimoto’s. ... Hashimoto’s thyroiditis . frequently coincides with insulin resistance, elevated HOMA-IR scores, and visceral adiposity even at normal BMI. Listen at CFP Weight Loss — clinical guide with Russell Clark, FNP-C. Read more: https://blog.cfpweightloss.com/microdosing-glp-1-trends-for-hashimoto-patients-risks-myths-and-red-flags-wo6d81